On September 18, 2026 the FDA issued a warning letter to Empower Clinic Services, LLC, operating as Empower Pharmacy, one of the largest 503A compounders of GLP-1 products in the country. The letter followed a November 2025 inspection and was published in late September. It is the clearest statement to date of how the FDA now reads compounded GLP-1 co-formulations, and it speaks to prescribers and ordering platforms as much as to pharmacies.
This article summarizes what the letter says, why it matters beyond one pharmacy, and what a clinic that still prescribes compounded GLP-1s for individual patients should change.
What the letter says
Based on published reporting and legal analysis of the letter:
- The products. The FDA cited tirzepatide combined with niacinamide and semaglutide combined with cyanocobalamin (vitamin B12). Both are combinations of an approved GLP-1 active ingredient with a vitamin or vitamin-like additive.
- Essentially copies. The FDA concluded that the co-formulations remained essentially copies of the FDA-approved semaglutide and tirzepatide products despite the added ingredient. This follows the agency's April 1, 2026 clarification, which used semaglutide plus B12 as its example of a product it may treat as a copy when the route matches and the strengths are within 10% of the commercial products.
- Volume as pretext. The letter stated that the volume of products being produced suggested the differences between the compounded and approved products were pretextual. Legal commentators describe this as the first GLP-1 warning letter to use that framing.
- Documentation failures. The FDA flagged templated significant-difference language and prescriptions with no significant-difference determination at all.
- Platforms. The letter pointed to third-party platforms that offer prescribers pre-selected options.
The letter also included observations from the inspection about the pharmacy's sterile compounding operations. Those are specific to the facility; the copy analysis is what generalizes.
Why it matters beyond Empower
Three things changed with this letter.
1. Adding a vitamin is not a strategy. Since the semaglutide shortage ended in February 2025, some compounders and telehealth programs have treated B12, B6 or similar additives as a routine way to distinguish a compounded product from the approved one. The April 2026 statement said that does not work on its own; the September letter applied it to real products at a named pharmacy.
2. Volume is now evidence. Before this letter, enforcement focused on documentation: was there a patient-specific determination, and was it credible? The FDA has added a second, independent test. If a pharmacy, or a program, is producing a "different" GLP-1 at scale, the scale itself suggests the difference is pretext. That cannot be fixed with better paperwork.
3. The whole chain is in scope. By naming templated statements and platforms with pre-selected options, the FDA described a workflow, not a pharmacy. Clinics, telehealth companies and the software they use are part of that workflow.
What a clinic should do now
For practices that still have patients with a documented need for a compounded GLP-1 product:
- Review every standing justification. If the same sentence appears on every GLP-1 prescription, retire it. The determination has to describe the actual difference for that patient (for example a strength, formulation or excipient the patient needs or cannot tolerate), not convenience, cost or preference.
- Prescribe the approved product where it fits. The compounded product is for the patient the approved product does not serve.
- Look at your own volume. A clinic whose GLP-1 prescriptions are overwhelmingly compounded co-formulations should expect the FDA's reasoning to apply to it.
- Check how your platform works. If a vendor pre-fills a formulation, a justification, or both, the letter is describing that vendor.
- Keep records. Chart notes, prescriptions and order records should show the individualized determination for each patient, patient by patient.
- Communicate honestly with patients. Compounded GLP-1s are not FDA-approved and are not generic versions of the brand products.
What the letter does not do
A warning letter is an enforcement notice of alleged violations addressed to one company. It is not a final adjudication, and it does not change the law. Compounded GLP-1 products are not banned: a 503A pharmacy may still compound one for an individual patient where it is not essentially a copy of the approved drug, and the FDA has restated that it does not generally intend to act against a 503A compounder filling four or fewer prescriptions of such a product in a calendar month. For 503B outsourcing facilities, the separate question of the 503B bulks list is covered in FDA's proposal to exclude semaglutide, tirzepatide and liraglutide.
Expect more letters and more litigation on this theory. Clinics that build their GLP-1 workflow around the individual patient, rather than around a product, are the ones the letter is not describing.
For how ordering works on ScriptLinkRx under these rules, see the compounded GLP-1 sourcing guide for clinics.
Sources
- FDA: Warning Letters (search "Empower Clinic Services")
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)
- Frier Levitt: FDA Warning Letter Targets Compounded GLP-1 Products
- Lengea Law: FDA Issues Warning Letter to Empower Pharmacy Over Compounded GLP-1 Copying and Quality Violations